Home › Companies › APOGEE THERAPEUTICS INC. › 2023-2024
At APOGEE THERAPEUTICS INC.'s shareholder meeting held June 5, 2024, in the 2023-2024 proxy season, 58 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,004 separate fund positions. On the most widely held item on that ballot — Approval of the grant of options to purchase 100,000 shares of the Company's common stock to a… — APOGEE THERAPEUTICS INC.'s filing reports the proposal as approved, with 99.1% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: APOGEE THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 7, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and APOGEE THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 5, 2024: 5 items on APOGEE THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024: 2 approved · 3 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore APOGEE THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are APOGEE THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 7, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Andrew Gottesdiener, M.D. | 33,888,258 | -- | -- | 6,873,344 | 805,441 | 83% | Not verified | — |
| Elect Director: Peter Harwin | 33,716,470 | -- | -- | 7,045,132 | 805,441 | 83% | Not verified | — |
| Elect Director: Michael Henderson, M.D. | 34,982,626 | -- | -- | 5,778,976 | 805,441 | 86% | Not verified | — |
| 2. Ratification of Independent Auditor The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024 | 41,560,000 | 2,163 | 4,880 | -- | 0 | 99.9% | Approved | — |
| 3. Approval of Director Option Grant The grant of options to a director to purchase 100,000 shares of the Company's voting common stock | 40,430,389 | 330,671 | 542 | -- | 805,441 | 99.1% | Approved | — |
Source: APOGEE THERAPEUTICS INC., Form 8-K, filed with the SEC on June 7, 2024 — read the filing on EDGAR.
Each item below shows how the 58 asset managers that disclosed a APOGEE THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors for terms expiring in 2027: Andrew Gottesdiener, M.D.
APOGEE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Andrew Gottesdiener, M.D.”): 33,888,258 for, 6,873,344 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 10,953,888 for, 1,768,598 withheld, 242,146 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,507,641 | 0 | 0 | 0 | For |
| Vanguard | 2,940,878 | 0 | 0 | 0 | For |
| BlackRock | 1,376,830 | 0 | 0 | 0 | For |
| T. Rowe Price | 934,631 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 596,239 | Withhold |
| AllianceBernstein | 276,278 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 273,793 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 241,373 | Withhold |
| Bridge Builder Trust | 12,689 | 0 | 194,436 | 0 | Mixed |
| State Street | 162 | 0 | 0 | 178,829 | Withhold |
| Hartford | 150,863 | 0 | 0 | 0 | For |
| Equitable | 123,333 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 115,033 | 0 | 0 | 0 | For |
| Invesco | 90,173 | 0 | 0 | 0 | For |
| John Hancock | 74,970 | 0 | 11,031 | 0 | Mixed |
| Brinker Capital Destinations Trust | 0 | 0 | 0 | 85,531 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 77,120 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 64,212 | Withhold |
| Principal | 51,426 | 0 | 0 | 4,940 | Mixed |
| TIAA | 56,324 | 0 | 0 | 0 | For |
| Northwestern Mutual | 51,113 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 46,535 | Withhold |
| RBB FUND, INC. | 0 | 0 | 0 | 40,582 | Withhold |
| TRUST FOR PROFESSIONAL MANAGERS | 0 | 0 | 36,120 | 0 | Abstain |
| Lincoln Financial | 0 | 0 | 0 | 33,700 | Withhold |
Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors for terms expiring in 2027: Michael Henderson, M.D.
APOGEE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Michael Henderson, M.D.”): 34,982,626 for, 5,778,976 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 11,183,248 for, 1,539,238 withheld, 242,146 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,507,641 | 0 | 0 | 0 | For |
| Vanguard | 2,940,878 | 0 | 0 | 0 | For |
| BlackRock | 1,376,830 | 0 | 0 | 0 | For |
| T. Rowe Price | 934,631 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 596,239 | Withhold |
| AllianceBernstein | 276,278 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 273,793 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 241,373 | Withhold |
| Bridge Builder Trust | 12,689 | 0 | 194,436 | 0 | Mixed |
| State Street | 178,775 | 0 | 0 | 216 | For |
| Hartford | 150,863 | 0 | 0 | 0 | For |
| Equitable | 123,333 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 115,033 | 0 | 0 | 0 | For |
| Invesco | 90,173 | 0 | 0 | 0 | For |
| John Hancock | 74,970 | 0 | 11,031 | 0 | Mixed |
| Brinker Capital Destinations Trust | 1,375 | 0 | 0 | 84,156 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 77,120 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 64,212 | Withhold |
| Principal | 51,426 | 0 | 0 | 4,940 | Mixed |
| TIAA | 56,324 | 0 | 0 | 0 | For |
| Northwestern Mutual | 51,113 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 46,535 | Withhold |
| RBB FUND, INC. | 0 | 0 | 0 | 40,582 | Withhold |
| TRUST FOR PROFESSIONAL MANAGERS | 0 | 0 | 36,120 | 0 | Abstain |
| Lincoln Financial | 33,700 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors for terms expiring in 2027: Peter Harwin
APOGEE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Peter Harwin”): 33,716,470 for, 7,045,132 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 10,863,715 for, 1,858,771 withheld, 242,146 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,507,641 | 0 | 0 | 0 | For |
| Vanguard | 2,940,878 | 0 | 0 | 0 | For |
| BlackRock | 1,376,830 | 0 | 0 | 0 | For |
| T. Rowe Price | 934,631 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 596,239 | Withhold |
| AllianceBernstein | 276,278 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 273,793 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 241,373 | Withhold |
| Bridge Builder Trust | 12,689 | 0 | 194,436 | 0 | Mixed |
| State Street | 162 | 0 | 0 | 178,829 | Withhold |
| Hartford | 150,863 | 0 | 0 | 0 | For |
| Equitable | 123,333 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 115,033 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 90,173 | Withhold |
| John Hancock | 74,970 | 0 | 11,031 | 0 | Mixed |
| Brinker Capital Destinations Trust | 0 | 0 | 0 | 85,531 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 77,120 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 64,212 | Withhold |
| Principal | 51,426 | 0 | 0 | 4,940 | Mixed |
| TIAA | 56,324 | 0 | 0 | 0 | For |
| Northwestern Mutual | 51,113 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 46,535 | Withhold |
| RBB FUND, INC. | 0 | 0 | 0 | 40,582 | Withhold |
| TRUST FOR PROFESSIONAL MANAGERS | 0 | 0 | 36,120 | 0 | Abstain |
| Lincoln Financial | 0 | 0 | 0 | 33,700 | Withhold |
Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.1% Approved · of votes cast
Description as filed by funds: Approval of the grant of options to purchase 100,000 shares of the Company's common stock to a director, Mark C. McKenna.
APOGEE THERAPEUTICS INC.’s own tally for this item (“3. Approval of Director Option Grant The grant of options to a director to purchase 100,000 shares of the Company's voting common stock”): 40,430,389 for, 330,671 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3: Approval of Director Option Grant The grant of options to a director to purchase 100,000 shares of the Company's voting common stock was approved as follows:”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 12,933,062 for, 31,570 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,507,641 | 0 | 0 | 0 | For |
| Vanguard | 2,940,878 | 0 | 0 | 0 | For |
| BlackRock | 1,376,830 | 0 | 0 | 0 | For |
| T. Rowe Price | 934,631 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 596,239 | 0 | 0 | 0 | For |
| AllianceBernstein | 276,278 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 273,793 | 0 | 0 | 0 | For |
| Charles Schwab | 241,373 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 207,125 | 0 | 0 | 0 | For |
| State Street | 178,991 | 0 | 0 | 0 | For |
| Hartford | 150,863 | 0 | 0 | 0 | For |
| Equitable | 123,333 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 115,033 | 0 | 0 | 0 | For |
| Invesco | 90,173 | 0 | 0 | 0 | For |
| John Hancock | 86,001 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 85,531 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 77,120 | 0 | 0 | 0 | For |
| Victory Capital | 64,212 | 0 | 0 | 0 | For |
| Principal | 56,366 | 0 | 0 | 0 | For |
| TIAA | 56,324 | 0 | 0 | 0 | For |
| Northwestern Mutual | 51,113 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 46,535 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 40,582 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 36,120 | 0 | 0 | 0 | For |
| Lincoln Financial | 33,700 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.
APOGEE THERAPEUTICS INC.’s own tally for this item (“2. Ratification of Independent Auditor The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024”): 41,560,000 for, 2,163 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of Independent Auditor The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024 was ratified as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 12,960,277 for, 4,355 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,507,641 | 0 | 0 | 0 | For |
| Vanguard | 2,940,878 | 0 | 0 | 0 | For |
| BlackRock | 1,376,830 | 0 | 0 | 0 | For |
| T. Rowe Price | 934,631 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 596,239 | 0 | 0 | 0 | For |
| AllianceBernstein | 276,278 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 273,793 | 0 | 0 | 0 | For |
| Charles Schwab | 241,373 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 207,125 | 0 | 0 | 0 | For |
| State Street | 178,991 | 0 | 0 | 0 | For |
| Hartford | 150,863 | 0 | 0 | 0 | For |
| Equitable | 123,333 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 115,033 | 0 | 0 | 0 | For |
| Invesco | 90,173 | 0 | 0 | 0 | For |
| John Hancock | 86,001 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 85,531 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 77,120 | 0 | 0 | 0 | For |
| Victory Capital | 64,212 | 0 | 0 | 0 | For |
| Principal | 56,366 | 0 | 0 | 0 | For |
| TIAA | 56,324 | 0 | 0 | 0 | For |
| Northwestern Mutual | 51,113 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 46,535 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 40,582 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 36,120 | 0 | 0 | 0 | For |
| Lincoln Financial | 33,700 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 58,304,801 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 7.73% |
| 2 | Vanguard | 5.04% |
| 3 | BlackRock | 2.36% |
| 4 | T. Rowe Price | 1.60% |
| 5 | FRANKLIN STRATEGIC SERIES | 1.02% |
| 6 | AllianceBernstein | 0.47% |
| 7 | DRIEHAUS MUTUAL FUNDS | 0.47% |
| 8 | Charles Schwab | 0.41% |
| 9 | Bridge Builder Trust | 0.36% |
| 10 | State Street | 0.31% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 11.86% | 13F |
| Entities affiliated with FMR LLC (Fidelity) | 8.61% | DEF14A |
| RTW Investments, LP | 4.65% | 13G |
| BlackRock | 4.61% | 13F |
| Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. | 4.34% | DEF14A |
| Entities affiliated with Deep Track Capital, LP | 3.99% | DEF14A |
| Wellington Management | 3.89% | 13F |
| Paragon | 3.87% | DEF14A |
| Vanguard Group | 3.85% | 13F |
| AI Biotechnology LLC | 3.76% | 13G |
Percentages above are of 58,304,801 shares outstanding, as reported by APOGEE THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from APOGEE THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
APOGEE THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
proxyvotesnow.com, “APOGEE THERAPEUTICS INC. 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/apogee-therapeutics-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.